GBM is also an immunologically quiet tumor, with low tumor mutational burden (TMB), few tumor infiltrating T cells (TILS), and low PD-1/PD-L1 expression, especially when compared to other cancers where immunotherapy has been the most successful [4, 5]. This evidence concerns the gene CD274 and neoplasm.